Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Ref Type||Journal Article|
|Authors||Tanoue T, Morita S, Plichta DR, Skelly AN, Suda W, Sugiura Y, Narushima S, Vlamakis H, Motoo I, Sugita K, Shiota A, Takeshita K, Yasuma-Mitobe K, Riethmacher D, Kaisho T, Norman JM, Mucida D, Suematsu M, Yaguchi T, Bucci V, Inoue T, Kawakami Y, Olle B, Roberts B, Hattori M, Xavier RJ, Atarashi K, Honda K|
|Title||A defined commensal consortium elicits CD8 T cells and anti-cancer immunity.|
|Abstract Text||There is a growing appreciation for the importance of the gut microbiota as a therapeutic target in various diseases. However, there are only a handful of known commensal strains that can potentially be used to manipulate host physiological functions. Here we isolate a consortium of 11 bacterial strains from healthy human donor faeces that is capable of robustly inducing interferon-γ-producing CD8 T cells in the intestine. These 11 strains act together to mediate the induction without causing inflammation in a manner that is dependent on CD103+ dendritic cells and major histocompatibility (MHC) class Ia molecules. Colonization of mice with the 11-strain mixture enhances both host resistance against Listeria monocytogenes infection and the therapeutic efficacy of immune checkpoint inhibitors in syngeneic tumour models. The 11 strains primarily represent rare, low-abundance components of the human microbiome, and thus have great potential as broadly effective biotherapeutics.|
|Molecular Profile||Treatment Approach|
|Gene Name||Source||Synonyms||Protein Domains||Gene Description||Gene Role|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|VE800||VE-800|VE 800||VE800 is a mixture comprised of 11 clonally-derived human commensal bacterial strains, which potentially enhances anti-tumor immune responses leading to reduced tumor growth (PMID: 30675064).|
|Gene||Variant||Impact||Protein Effect||Variant Description||Associated with drug Resistance|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||colon adenocarcinoma||not applicable||VE800||Preclinical||Actionable||In a preclinical study, VE800 treatment inhibited tumor growth in a mouse model of colon adenocarcinoma (PMID: 30675064).||30675064|
|Unknown unknown||colon adenocarcinoma||not applicable||unspecified CTLA4 antibody + VE800||Preclinical||Actionable||In a preclinical study, CTLA4 antibody treatment supplemented with VE800 inhibited tumor growth in a mouse model of colon adenocarcinoma (PMID: 30675064).||30675064|
|Unknown unknown||colon adenocarcinoma||not applicable||unspecified PD-1 antibody + VE800||Preclinical||Actionable||In a preclinical study, PD1-antibody treatment supplemented with VE800 inhibited tumor growth in mouse models of colon adenocarcinoma (PMID: 30675064).||30675064|